2-(氯甲基)-6-苯基吡啶 | 147937-33-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 2-(氯甲基)-6-苯基吡啶
• 英文名称: 2-(chloromethyl)-6-phenylpyridine
• CAS: 147937-33-5
• 化学式: C₁₂H₁₀ClN
• 分子量: 203.671
• InChiKey: NPSWBGSNFIEDJD-UHFFFAOYSA-N

物化性质

• 沸点：
  316.3±27.0 °C(Predicted)
• 密度：
  1.159±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.08
• 拓扑面积：
  12.9
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  2-(氯甲基)-6-苯基吡啶 在 sodium hydroxide 、 sodium azide 、 氯化铵 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 38.25h， 生成 2-phenyl-6-[[4-[3-(2H-tetrazol-5-yl)propoxy]phenoxy]methyl]pyridine
  参考文献：
  名称：

  Development of a novel series of (2-quinolinylmethoxy)phenyl-containing compounds as high-affinity leukotriene receptor antagonists. 1. Initial structure-activity relationships

  摘要：

  This series of reports describes the development of orally active, highly potent, specific antagonists of the peptidoleukotrienes containing a (2-quinolinylmethoxy)phenyl moiety. Described in this first report are the structure-activity relationships that led to a more than a 20-fold improvement of the potency and selectivity of the initial chemical lead (RG 5901). From this series of compounds, RG 7152 (16) was identified and selected for further evaluation in the clinic as an antiasthmatic agent. Compound 16 competitively inhibits [3H]LTD4 binding to membranes from guinea pig lung (Ki = 38 +/- 6 nM) and the spasmogenic activity of LTC4, LTD4, and LTE4 in parenchymal lung strips from guinea pigs. Unlike the original lead (RG 5901), compound 16 does not inhibit 5-lipoxygenase from guinea pig PMNs. Following oral administration to guinea pigs, 16 blocks LTD4-induced dermal permeability (ED50 = 6.9 mg/kg), LTD4-induced bronchoconstriction (ED50 = 1.1 mg/kg), antigen-induced bronchoconstriction (ED50 = 2.5 mg/kg), and anaphylactic-induced mortality (ED50 = 16 mg/kg). These studies on structure-activity relationships indicate that there is a requirement for an acidic function and the presence of the (2-quinolinylmethoxy)phenyl moiety in a specific geometric arrangement.

  DOI：

  10.1021/jm00166a016
• 作为产物：
  描述：

  2-溴-6-甲基吡啶 在 四(三苯基膦)钯 、 氯化亚砜 、 乙酸酐 、 sodium carbonate 、 间氯过氧苯甲酸 作用下， 以 二氯甲烷 、 氯仿 、 水 、 甲苯 为溶剂， 反应 17.0h， 生成 2-(氯甲基)-6-苯基吡啶
  参考文献：
  名称：

  Inhibition of 1-Deoxy-d-Xylulose-5-Phosphate Reductoisomerase by Lipophilic Phosphonates: SAR, QSAR, and Crystallographic Studies

  摘要：

  1-Deoxy-D-xylulose-5-phosphate reductoisomerase (DXR) is a novel target for developing new antibacterial (including antituberculosis) and antimalaria drugs. Forty-one lipophilic phosphonates, representing a new class of DXR inhibitors, were synthesized, among which 5-phenylpyridin-2-ylmethylphosphonic acid possesses the most activity against E. coli DXR (EcDXR) with a K-i of 420 nM. Structure-activity relationships (SAR) are discussed, which can be rationalized using our EcDXR:inhibitor structures, and a predictive quantitative SAR (QSAR) model is also developed. Since inhibition studies of DXR from Mycobacterium tuberculosis (MtDXR) have not been performed well, 48 EcDXR inhibitors with a broad chemical diversity were found, however, to generally exhibit considerably reduced activity against MtDXR. The crystal structure of a, MtDXR:inhibitor complex reveals the flexible loop containing the residues 198-208 has no strong interactions with the 3,4-dichlorophenyl group of the inhibitor, representing a structural basis for the reduced activity. Overall, these results provide implications in the future design and development of potent DXR inhibitors.

  DOI：

  10.1021/jm200363d

文献信息

• [EN] FUSED PYRIMIDINE DERIVATIVES HAVING INHIBITORY ACTIVITY ON FMS KINASES<br/>[FR] DÉRIVÉS DE PYRIMIDINE FUSIONNÉS AYANT UNE ACTIVITÉ INHIBITRICE SUR LES FMS KINASE
  申请人：HANMI PHARM IND CO LTD

  公开号：WO2014003483A1

  公开（公告）日：2014-01-03

  Disclosed are a fused pyrimidine derivative of formula (I), and a pharmaceutically acceptable salt, stereoisomer, hydrate and solvate thereof, which have an excellent inhibitory activity on FMS kinases, and a pharmaceutical composition comprising the same is effective in preventing or treating diseases caused by abnormal activation of FMS kinases such as immunologic diseases, metabolic diseases, inflammatory diseases, cancers and tumors.

  本文披露了一种公式（I）的融合嘧啶衍生物，以及其药用可接受的盐、立体异构体、水合物和溶剂合物，具有对FMS激酶的出色抑制活性，包含该物质的药物组合物在预防或治疗由FMS激酶异常激活引起的疾病方面具有有效性，如免疫疾病、代谢性疾病、炎症性疾病、癌症和肿瘤。
• Is the Bis(-oxo)dicopper Core Capable of Hydroxylating an Arene?
  作者：Patrick L. Holland、Kenton R. Rodgers、William B. Tolman

  DOI：10.1002/(sici)1521-3773(19990419)38:8<1139::aid-anie1139>3.0.co;2-0

  日期：1999.4.19

  Direct attack of the bis(μ-oxo)dicopper core on an arene appears feasible in tyrosinase and model complexes on the basis of studies of new [Cu(III) 2 (μ-O)2 ](2+) compounds supported by bidentate imine/amine ligands. In the first demonstration of such reactivity for a bis(μ-oxo)dicopper core, decomposition of these intermediates caused hydroxylation of a pendant phenyl ring [Eq. (a)] in a reaction

  在酪氨酸酶和模型配合物中，对双（μ-氧代）双铜核的直接攻击似乎是可行的，这是基于对双齿酸所支持的新[Cu（III）2（μ-O）2]（2+）化合物的研究亚胺/胺配体。在对双（μ-氧代）二铜核具有这种反应性的第一个证明中，这些中间体的分解引起了苯环侧链的羟基化。（a）]的反应类似于酪氨酸酶催化的反应。
• SAR Study of 1-Aryl-4-(phenylarylmethyl)piperazines as Ligands for Both Dopamine D2 and Serotonin 5-HT1A Receptors Showing Varying Degrees of (Ant)agonism. Selection of a Potential Atypical Antipsychotic
  作者：Roelof Willem Feenstra、Adri van den Hoogenband、Cornelis Nicolaas Jozef Stroomer、Herman Heinrich van Stuivenberg、Martin Theodorus Maria Tulp、Stephen Kenneth Long、Johannes Antonius Maria van der Heyden、Cornelis Gerrit Kruse

  DOI：10.1248/cpb.54.1326

  日期：——

  The syntheses of several 1-aryl-4-(arylpyridylmethyl)piperazines (4) and their affinities for dopamine D2 and serotonin 5-HT1A receptors are described. The compounds were evaluated both in vitro and in vivo, resulting in the identification of the drug candidate SLV313 (4e) with equipotent and full D2 receptor antagonism and 5-HT1A receptor agonism. Minor structural modifications in SLV313 revealed the possibility of designing compounds possessing varying degrees of partial agonism on one or both target receptors.

  本文描述了多种1-芳基-4-(芳基吡啶甲基)哌嗪（4）的合成及其对多巴胺D2和5-羟色胺1A受体的亲和力。这些化合物在体外和体内均进行了评估，最终确定了候选药物SLV313（4e）具有等效且完全的D2受体拮抗作用和5-HT1A受体激动作用。对SLV313进行细微的结构修改，可以设计出对一个或两个靶标受体具有不同程度部分激动作用的化合物。
• 2-aryl substituted pyridyl-containing phenyl sulfonamido compounds as
  申请人：American Home Products Corporation

  公开号：US04942236A1

  公开（公告）日：1990-07-17

  There are disclosed compounds of the formula ##STR1## n is 0-5; R.sup.2 is, independently, hydrogen, loweralkyl, loweralkoxy, trifluoromethyl or halo; ##STR2## W represents a bond or ##STR3## m is 1-15; R.sup.4 is hydrogen or loweralkyl; R.sup.5 is lower alkyl, monofluoroloweralkyl, difluoroloweralkyl, polyfluoroloweralkyl, perfluoroloweralkyl or ##STR4## or a pharmaceutically acceptable salt thereof, and their use in the treatment of leukotriene-mediated naso-bronchial obstructive airpassageway conditions, such as allergic rhinitis, allergic bronchial asthma and the like, and as antiinflammatory agents.

  公开了一种化合物，其化学式为##STR1##其中，n为0-5；R.sup.2是独立的氢、低碳基、低碳氧基、三氟甲基或卤素；##STR2##W表示键或##STR3##m为1-15；R.sup.4是氢或低碳基；R.sup.5是低碳基、单氟低碳基、二氟低碳基、多氟低碳基、全氟低碳基或##STR4##或其药学上可接受的盐，以及它们在治疗白三烯介导的鼻-支气管阻塞性气道疾病，如过敏性鼻炎、过敏性支气管哮喘等，以及作为抗炎药物的用途。
• 2-aryl substituted heterocyclic compounds as antiallergic and
  申请人：American Home Products Corporation

  公开号：US04826990A1

  公开（公告）日：1989-05-02

  There are disclosed compounds of the formula ##STR1## wherein X is ##STR2## Y is ##STR3## Z is ##STR4## R.sup.1 is ##STR5## n is 0-5; R.sup.2 is hydrogen, loweralkyl, loweralkoxy, lower alkoxycarbonyl, trifluoromethyl, nitro, cyano or halo; R.sup.3 is ##STR6## W represents a bond or ##STR7## m is 1-15; R.sup.4 is hydrogen or loweralkyl; R.sup.5 is lower alkyl, monofluoroloweralkyl, difluoroloweralkyl, polyfluoroloweralkyl, perfluoroloweralkyl or ##STR8## R.sup.6 is hydrogen, lower alkyl, ##STR9## and the pharmaceutically acceptable salts thereof, and their use in the treatment of leukotriene-mediated naso-bronchial obstructive airpassageway conditions, such as allergic rhinitis, allergic bronchial asthma and the like, and as antiinflammatory agents.

  公开了以下式子的化合物 ##STR1## 其中 X 是 ##STR2## Y 是 ##STR3## Z 是 ##STR4## R.sup.1 是 ##STR5## n 是 0-5; R.sup.2 是 氢，低烷基，低烷氧基，低烷氧羰基，三氟甲基，硝基，氰基或卤素; R.sup.3 是 ##STR6## W 代表键或 ##STR7## m 是 1-15; R.sup.4 是 氢或低烷基; R.sup.5 是 低烷基，单氟低烷基，二氟低烷基，多氟低烷基，全氟低烷基或 ##STR8## R.sup.6 是 氢，低烷基，##STR9##及其药学上可接受的盐，并且它们在治疗白三烯介导的鼻支气管阻塞性通气道疾病，如过敏性鼻炎，过敏性支气管哮喘等方面的用途，以及作为抗炎剂。